文献速递肝病

非甾体法尼醇X受体激动剂西洛非索(GS-9674)改善原发性硬化性胆管炎患者的胆汁淤积和肝损伤标志物

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
PubMed 文献 · Hepatology · 2019-03-10

这项II期双盲安慰剂对照研究评估了非甾体法尼醇X受体激动剂西洛非索在无肝硬化的大胆管型原发性硬化性胆管炎患者中的安全性和有效性。52例患者随机接受西洛非索100 mg(n=22)、30 mg(n=20)或安慰剂(n=10)口服每日一次共12周。西洛非索耐受性良好,100 mg组第12周血清ALP中位下降21%(P=0.029 vs 安慰剂),GGT下降30%(P<0.001),ALT下降49%(P=0.009),AST下降42%(P=0.019)。

要点

  • 西洛非索100 mg组第12周血清ALP中位下降21%,与安慰剂相比差异有统计学意义(P=0.029)。
  • 西洛非索100 mg组GGT下降30%、ALT下降49%、AST下降42%,均与安慰剂有显著差异。
  • 西洛非索与安慰剂的不良事件相似;2级或3级瘙痒发生率100 mg组14%、30 mg组20%、安慰剂组40%。

核心结论

  • 在这项12周随机安慰剂对照研究中,西洛非索耐受性良好,并使原发性硬化性胆管炎患者的肝脏生化指标和胆汁淤积标志物得到显著改善。

研究设计与样本

  • II期双盲、安慰剂对照研究,纳入无肝硬化的大胆管型原发性硬化性胆管炎患者。
  • 患者随机接受西洛非索100 mg(n=22)、30 mg(n=20)或安慰剂(n=10)口服每日一次,共12周。
  • 所有患者基线血清ALP > 1.67倍正常上限,总胆红素 ≤ 2 mg/dL。
  • 共52例患者随机化,中位年龄43岁,58%为男性,60%合并炎症性肠病,46%使用熊去氧胆酸。

主要发现

  • 基线血清ALP中位值为348 U/L(四分位距288-439),胆红素中位值为0.7 mg/dL(0.5-1.0)。
  • 第12周时,西洛非索100 mg组血清ALP中位下降21%(P=0.029 vs 安慰剂),GGT下降30%(P<0.001),ALT下降49%(P=0.009),AST下降42%(P=0.019)。
  • 西洛非索较安慰剂降低血清C4;100 mg组胆汁酸下降幅度最大。
  • 接受和未接受熊去氧胆酸治疗的患者之间,ALP相对下降幅度相似。
  • 第12周时,西洛非索治疗患者中ALP相对下降≥25%者,其血清ALT、AST、GGT、金属蛋白酶组织抑制因子1、C反应蛋白和胆汁酸的下降幅度大于无应答者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary sclerosing cholangitis (PSC) represents a major unmet medical need. In a phase II double-blind, placebo-controlled study, we tested the safety and efficacy of cilofexor (formerly GS-9674), a nonsteroidal farnesoid X receptor agonist in patients without cirrhosis with large-duct PSC. Patients were randomized to receive cilofexor 100 mg (n = 22), 30 mg (n = 20), or placebo (n = 10) orally once daily for 12 weeks. All patients had serum alkaline phosphatase (ALP) > 1.67 × upper limit of normal and total bilirubin ≤ 2 mg/dL at baseline. Safety, tolerability, pharmacodynamic effects of cilofexor (serum C4 [7α-hydroxy-4-cholesten-3-one] and bile acids), and changes in liver biochemistry and serum fibrosis markers were evaluated. Overall, 52 patients were randomized (median age 43 years, 58% male, 60% with inflammatory bowel disease, 46% on ursodeoxycholic acid). Baseline median serum ALP and bilirubin were 348 U/L (interquartile range 288-439) and 0.7 mg/dL (0.5-1.0), respectively. Dose-dependent reductions in liver biochemistry were observed. At week 12, cilofexor 100 mg led to significant reductions in serum ALP (median reduction -21%; P = 0.029 versus placebo), gamma-glutamyl transferase (-30%; P < 0.001), alanine aminotransferase (ALT) (-49%; P = 0.009), and aspartate aminotransferase (-42%; P = 0.019). Cilofexor reduced serum C4 compared with placebo; reductions in bile acids were greatest with 100 mg. Relative reductions in ALP were similar between ursodeoxycholic acid-treated and untreated patients. At week 12, cilofexor-treated patients with a 25% or more relative reduction in ALP had greater reductions in serum alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, tissue inhibitor of metalloproteinase 1, C-reactive protein, and bile acids than nonresponders. Adverse events were similar between cilofexor and placebo-treated patients. Rates of grade 2 or 3 pruritus were 14% with 100 mg, 20% with 30 mg, and 40% with placebo. Conclusion: In this 12-week, randomized, placebo-controlled study, cilofexor was well tolerated and led to significant improvements in liver biochemistries and markers of cholestasis in patients with PSC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Trauner M, Gulamhusein A, Hameed B, et al. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019. PMID: 30661255. doi:10.1002/hep.30509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。